Author name: andrewshd

THE LOCALIST SD Precision Medicine disrupts the medical world

Mindera Health is disrupting the world of medicine. Ashley takes you inside their Carlsbad headquarters to see how this new psoriasis predictive test is changing lives for the better. Mindera Health founder Toby Dickerson explains it all.   See More: Precision Medicine disrupts the medical world | FOX 5 San Diego & KUSI News The […]

THE LOCALIST SD Precision Medicine disrupts the medical world Read More »

Koya Medical Announces Topline Results from Its Latest Trial

Koya Medical, today announces topline results from its TEAYS trial. TEAYS (NCT05507346) is a prospective multi-center, randomized cross-over study comparing lower extremity lymphedema treatment effectiveness of Dayspring?, Koya’s non-pneumatic compression device (NPCD) with a traditional advanced pneumatic compression device (APCD).   The study met its primary endpoints, achieving statistically significant differences in limb volume reduction,

Koya Medical Announces Topline Results from Its Latest Trial Read More »

Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine

Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with LivinitiTM, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to

Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine Read More »

Procyrion Closes $57.7 Million in Series E Financing

HOUSTON, TX – February 5, 2024 – Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. These funds will be used to support the ongoing DRAIN-HF

Procyrion Closes $57.7 Million in Series E Financing Read More »

Eirion Therapeutics to Present at the 2024 IMCAS World Congress

February 2, 2024 – Woburn, MA Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris. Chief Executive Officer and President, Jon

Eirion Therapeutics to Present at the 2024 IMCAS World Congress Read More »

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology

HOUSTON, TX – NOVEMBER 30, 2023 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company’s IDE pivotal trial. The DRAIN-HF (Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure) study will evaluate the Aortix™ percutaneous

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology Read More »

Centese, Inc. Secures Series B Funding and Strengthens Board With New Director –

Company secures funding to fuel expansion of its Thoraguard® System; adds veteran medtech leader Timothy Still to Board of Directors Centese, Inc., a leader in digital surgery technology, announces the successful closing of its $15M Series B funding round. The round, led by Medical Technology Venture Partners with participation from new and existing investors, will

Centese, Inc. Secures Series B Funding and Strengthens Board With New Director – Read More »